IL6 and Axenfeld-Rieger syndrome: Moreover, the integration of molecular biomarkers that are known to manifest in the prodromal and/or late ARS phases (Flt3 ligand, citrulline, C-reactive protein, and serum amylase IL-6) may contribute to our algorithm design in improving accuracy in determining the degree of an RC condition at various time points [15, 28, 38–40].